These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23902971)

  • 21. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension.
    Uzui H; Morishita T; Nakano A; Amaya N; Fukuoka Y; Ishida K; Arakawa K; Lee JD; Tada H
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):304-9. PubMed ID: 24288395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effect of fixed-dose combination tablets of candesartan cilexetil/amlodipine versus olmesartan medoxomil/azelnidipine on laboratory parameters in patients with hypertension: a retrospective cohort study.
    Susa N; Nishida Y; Yada Y; Nakayama T; Asai S; Takahashi Y
    Clin Exp Hypertens; 2016; 38(2):173-9. PubMed ID: 26453437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of olmesartan and enalapril at low or high doses on cardiac, renal and vascular interstitial matrix in spontaneously hypertensive rats.
    Porteri E; Rodella L; Rizzoni D; Rezzani R; Paiardi S; Sleiman I; De Ciuceis C; Boari GE; Castellano M; Bianchi R; Agabiti-Rosei E
    Blood Press; 2005; 14(3):184-92. PubMed ID: 16036499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.
    Nagasu H; Satoh M; Yorimitsu D; Tomita N; Sasaki T; Kashihara N
    Kidney Blood Press Res; 2011; 34(2):87-96. PubMed ID: 21273789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effects of olmesartan and azelnidipine on atrial structural remodeling in spontaneously hypertensive rats.
    Okamura K; Ito M; Tanaka K; Chinushi M; Adachi T; Mitsuma W; Hirono S; Nakazawa M; Kodama M; Aizawa Y
    Pharmacology; 2009; 83(6):360-6. PubMed ID: 19440002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous treatment with azelnidipine and olmesartan inhibits apoptosis of Hl-1 cardiac myocytes expressing E334k cMyBPC.
    Bahrudin U; Ikeda N; Utami SB; Maharani N; Morikawa K; Li P; Sobirin MA; Hasegawa A; Sakata S; Endo R; Rifqi S; Shirayoshi Y; Yamamoto K; Ninomiya H; Hisatome I
    Drug Res (Stuttg); 2013 Oct; 63(10):515-20. PubMed ID: 23740383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
    Matsui Y; O'Rourke MF; Hoshide S; Ishikawa J; Shimada K; Kario K
    Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis.
    Tanigawara Y; Yoshihara K; Kuramoto K; Arakawa K
    Drug Metab Pharmacokinet; 2009; 24(4):376-88. PubMed ID: 19745564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
    Iwai M; Li HS; Chen R; Shiuchi T; Wu L; Min LJ; Li JM; Tsuda M; Suzuki J; Tomono Y; Tomochika H; Mogi M; Horiuchi M
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats.
    Lukic-Panin V; Kamiya T; Zhang H; Hayashi T; Tsuchiya A; Sehara Y; Deguchi K; Yamashita T; Abe K
    Brain Res; 2007 Oct; 1176():143-50. PubMed ID: 17904110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats.
    Fan YY; Kohno M; Nakano D; Hitomi H; Nagai Y; Fujisawa Y; Lu XM; Fu H; Du J; Ohmori K; Hosomi N; Kimura S; Kiyomoto H; Nishiyama A
    J Hypertens; 2009 Sep; 27(9):1855-62. PubMed ID: 19633569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olmesartan with azelnidipine versus with trichlormethiazide on home blood pressure variability in patients with type II diabetes mellitus.
    Ushigome E; Matsumoto S; Oyabu C; Ushigome H; Yokota I; Hasegawa G; Nakamura N; Tanaka M; Yamazaki M; Fukui M
    J Am Soc Hypertens; 2017 Mar; 11(3):140-147. PubMed ID: 28089902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker].
    Sada T; Saito H
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):539-47. PubMed ID: 14639008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury.
    Hilgers KF; Hartner A; Porst M; Mai M; Wittmann M; Hugo C; Ganten D; Geiger H; Veelken R; Mann JF
    Kidney Int; 2000 Dec; 58(6):2408-19. PubMed ID: 11115074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.
    Kimura Y; Hirooka Y; Sagara Y; Sunagawa K
    Clin Exp Hypertens; 2007 Jan; 29(1):13-21. PubMed ID: 17190727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central blood pressure under angiotensin and calcium channel blockade.
    Safar ME; Protogerou A; Blacher J
    Hypertension; 2009 Oct; 54(4):704-6. PubMed ID: 19667254
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats.
    Kim S; Ohta K; Hamaguchi A; Yukimura T; Miura K; Iwao H
    Br J Pharmacol; 1996 Jun; 118(3):549-56. PubMed ID: 8762077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers.
    Cheng XW; Okumura K; Kuzuya M; Jin Z; Nagata K; Obata K; Inoue A; Hirashiki A; Takeshita K; Unno K; Harada K; Shi GP; Yokota M; Murohara T
    J Cardiovasc Pharmacol; 2009 Jul; 54(1):47-56. PubMed ID: 19528815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.